The following table summarizes the key terms and activity to date for these arrangements (in millions except percentages):
|
|
|
|
Item |
2025 OMERS Agreement |
2022 OMERS Agreement |
2019 RPI Agreement |
Agreement counterparty |
OMERS |
OMERS |
RPI |
Contract execution date |
November 2025 |
July 2022 |
December 2019 |
Upfront payment to Company |
$400 |
$500 |
$320 |
Transaction costs |
$8 |
$9 |
$6 |
Territories |
U.S. and Canada |
U.S. and Canada |
EU, U.K., and Switzerland |
Percentage of royalties sold |
25%* |
30% |
100% |
Royalty start date |
January 1, 2028 |
April 1, 2023 |
January 1, 2020 |
CAP |
$620 |
$725 |
$608 prior to Dec 31, 2030 or until aggregate payments reach $800 |
Royalties earned from inception to June 30, 2026 |
$— |
$246 |
$144 |
Effective annual interest rate (as of June 30, 2026) |
9.2% |
7.3% |
5.5% |
* In addition, OMERS will continue to receive 30% of Crysvita net sales in the U.S. and Canada following the achievement of $725 million in aggregate payments under the 2022 OMERS Agreement. |
|